Personalis, Inc. Launches ImmunoID NeXT, the First Platform Providing Characterization of a Tumor and Its Microenvironment From a Single Sample

MENLO PARK, Calif.–(BUSINESS WIRE)–Personalis, Inc., a leader in advanced genomics for precision oncology,
today announced the launch of its universal cancer immunogenomics
platform, ImmunoID NeXT™. This is the first platform to enable
comprehensive analysis of both a tumor and its microenvironment from a
single sample.

Personalis CEO, John West, said, “While the success of checkpoint
blockade has been hugely promising, it’s increasingly apparent that
predicting response to immunotherapies and developing new ones requires
a more comprehensive approach to tumor immunogenomics. With ImmunoID
NeXT
, it’s now possible to characterize the complex interactions
between the tumor cells and immune cells of the microenvironment using a
single platform. This means researchers no longer have to make the
difficult choice of which biomarkers to analyze due to sample
limitations, particularly when dealing with FFPE specimens.”

The unique design of the ImmunoID NeXT Platform facilitates the delivery
of therapeutic and diagnostic biomarker information across ~20,000 genes
from DNA and RNA, including:

  • Neoantigen identification and characterization
  • Human leukocyte antigens (HLA) typing
  • Tumor infiltrating adaptive immune cells

    • T-cell receptor (TCR) repertoire (α, β, γ, and δ chains)
    • B-cell receptor (BCR) repertoire (heavy and light chains)
  • Tumor infiltrating innate immune cells
  • Immune response and tumor escape mechanisms
  • Neoantigen load and tumor mutational burden (TMB)
  • Microsatellite instability (MSI) status
  • Oncoviral detection
  • Germline genomic variation

Personalis is offering pharmaceutical customers the opportunity to
participate in an Early Access Program beginning in January, 2019. The
company also anticipates the release of a clinical diagnostic test based
on this platform in 2019.

Personalis will be presenting new data at the Society for Immunotherapy
of Cancer’s (SITC) Annual Meeting in Washington, D.C., November 8-11,
2018. Personalis representatives will also be available to discuss the
ImmunoID NeXT Platform at the company’s exhibit (Booth #617).

About Personalis, Inc.

Personalis, Inc. is a leader in advanced genomics for precision oncology
translational research and clinical trials, dedicated to enabling the
development of the next generation of oncology therapeutics. The
company’s ImmunoID NeXT Platform comprehensively characterizes the tumor
and the tumor microenvironment, facilitating the analysis of key
predictive and investigational oncology biomarkers from a single sample.
The Personalis Clinical Laboratory is GxP aligned as well as
CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and
follow Personalis on Twitter (@PersonalisInc).

الموقع يستعمل RSS Poster بدعم القاهرة اليوم